HanKang Capital

Lilly Asia Ventures is a biomedical venture capital firm that originated in 2008 as an Eli Lilly corporate venture subsidiary and later became an independent investment manager.

ShoreVest is a China-focused private credit investment manager. Its platform combines local origination, underwriting, legal structuring, asset servicing and portfolio management, with offices in Guangzhou, Shanghai, Beijing and Hong Kong.

Qiming Venture Partners is a top-tier VC firm with outstanding reputation. With our exceptional investment performances, we have been widely recognized by investors from around the world.We have a reputation for being entrepreneur friendly.

YuanBio Venture Capital is a China-based healthcare venture capital firm investing in early- and growth-stage companies across biotechnology, medical devices, diagnostics and healthcare services.

CoStone Capital is a Shenzhen-headquartered Chinese private markets manager. Its strategy spans early venture and private equity, including growth investments and buyouts.

YF Capital invests in emerging industries and advanced technologies through private equity funds. Its strategy spans hard technology, artificial intelligence, clean energy, enterprise services, healthcare and consumer businesses.

Hillhouse is a global investment firm that began investing in public equities, later added a private-equity strategy, and now invests across all stages of company life cycles.

CDH Investments is a diversified alternative asset manager with private-equity, venture-and-growth, private-credit, public-equity, and real-asset activities; VGC is its venture-and-growth unit.